UBS AM
CCCC icon

UBS AM’s C4 Therapeutics CCCC Stock Holding History

UBS AM’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-39,287
Closed -$123K – 2609
2023
Q2 		$123K Hold
39,287
– – ﹤0.01% 2624
2023
Q1 		$123K Buy
39,287
+9,994
+34% +$58.8K ﹤0.01% 2624
2022
Q4 		$173K Buy
+29,293
New +$243K ﹤0.01% 2462

Other funds holding CCCC

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

UBS AM's CCCC Position: Q3 2023 in Review

UBS AM sold out of C4 Therapeutics (CCCC) in Q3 2023, closing a stake of 39,287 shares — an estimated $123K sold.

UBS AM first reported a position in CCCC in Q4 2022 and held it in 3 quarters. The position peaked at $173K in Q4 2022. 83 funds tracked by Wall St. Rank hold CCCC as of Q3 2023.

  • UBS AM reported no remaining C4 Therapeutics position as of Q3 2023 after selling out during the quarter.
  • UBS AM sold 39,287 C4 Therapeutics shares in Q3 2023, an estimated $123K.
  • UBS AM first reported a position in C4 Therapeutics in Q4 2022 and held it in 3 quarters.
  • UBS AM's C4 Therapeutics position peaked at $173K in Q4 2022.
  • 83 funds tracked by Wall St. Rank held C4 Therapeutics as of Q3 2023.

Based on UBS AM's 13F filing for Q3 2023, filed 13 Nov 2023.